HC Wainwright Trims Valneva (NASDAQ:VALN) Target Price to $23.00

Valneva (NASDAQ:VALN) had its price target reduced by HC Wainwright from $26.00 to $23.00 in a research note released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.38) EPS.

Valneva Price Performance

Shares of NASDAQ VALN opened at $6.21 on Wednesday. The stock has a market cap of $432.46 million, a PE ratio of -15.15 and a beta of 2.19. Valneva has a fifty-two week low of $5.70 and a fifty-two week high of $14.49. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.15 and a current ratio of 2.63. The stock has a fifty day moving average of $7.06 and a 200-day moving average of $7.57.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02. The company had revenue of $40.97 million during the quarter, compared to analysts’ expectations of $46.83 million. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%. Equities research analysts anticipate that Valneva will post 0.02 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. boosted its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 as of its most recent SEC filing. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.